Oncology innovation is increasingly extending beyond what therapies achieve to how effectively care can be delivered. Across Asia-Pacific, the shift from intravenous (IV) to subcutaneous (SC) delivery illustrates this evolution, with the potential to reduce treatment burden, improve operational efficiency and create more flexible care pathways. Yet the value of these benefits is recognized differently across healthcare systems, stakeholders and clinical contexts.

This white paper explores what delivery innovation means for patients, healthcare professionals, payers, policymakers and pharmaceutical companies across APAC. It examines where SC can create the greatest value, the strategic considerations for manufacturers evaluating SC investment, and how stronger stakeholder alignment and real-world evidence can help translate delivery innovation into meaningful patient, system and commercial impact.